An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Exclusion Criteria

• •* Are poorly compliant with their current insulin regimen, as defined by their HCP
• •* Are poorly compliant with prescribed blood glucose self monitoring, as defined by their HCP
• •* Have experienced recurrent patient-ascertained severe hypoglycemia requiring assistance during the past 6 months
• •* Have hypoglycemia unawareness
• •* Have a confirmed diagnosis of gastroparesis
• •* Require the use of drugs that stimulate gastrointestinal motility
• •* Are female and pregnant or lactating and for whom the HCP determines the potential benefit does not justify the potential risk to the fetus or infant
• •* Have been treated with SYMLIN within 3 months prior to study start